Compares mezigdomide with pomalidomide in relapsed or refractory multiple myeloma
Tests mezigdomide, bortezomib and dexamethasone against pomalidomide combination in adults with myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Key facts
- Where
- Ankara, Istanbul, Izmir, Kayseri, and Samsun, TürkiyeSee the 6 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which of these best describes your myeloma treatment so far?
- Have you ever taken lenalidomide (also called Revlimid), a tablet medicine for myeloma?
- Has a doctor told you that your myeloma can be measured in your blood or urine tests?
Source: NCT05519085, who can take part
Where in Türkiye
- AnkaraAnkara, TürkiyeNo longer taking part
- AnkaraAnkara, TürkiyeNo longer taking part
- IstanbulIstanbul, TürkiyeNo longer taking part
- IzmirIzmir, TürkiyeNo longer taking part
- KayseriKayseri, TürkiyeNo longer taking part
- SamsunSamsun, TürkiyeNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Celgene
- Trial code
- NCT05519085
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.Read full original descriptionShow less
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Inclusion: Participant has documented diagnosis of MM and measurable disease, defined as any of the following:; M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or; M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP); For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio; Participants received 1 to 3 prior lines of antimyeloma therapy; Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.
Exclusion: Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:; Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks (or less frequently) are not excluded; Participants who progressed while being treated with ixazomib monotherapy maintenance ≥ 6 months prior to the time of starting study treatment are not excluded; For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity; Participant has had prior treatment with mezigdomide or pomalidomide; Other protocol-defined Inclusion/Exclusion criteria apply.